Elisa R Zanier1, Rosalia Zangari, Lea Munthe-Fog, Estrid Hein, Tommaso Zoerle, Valeria Conte, Franca Orsini, Mauro Tettamanti, Nino Stocchetti, Peter Garred, Maria-Grazia De Simoni. 1. From the IRCCS-Istituto di Ricerche Farmacologiche Mario Negri (E.R.Z., R.Z., F.O., M.T., M.-G.D.S.), Department of Neuroscience, Milan; Department of Physiopathology and Transplant, Milan University and Neuro ICU (R.Z., T.Z., V.C., N.S.), Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy; and Laboratory of Molecular Medicine (L.M.-F., E.H., P.G.), Department of Clinical Immunology, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark.
Abstract
OBJECTIVES: To assess the involvement of ficolin-3, the main initiator of the lectin complement pathway (LCP), in subarachnoid hemorrhage (SAH) pathology and outcome. METHODS: In this preliminary exploratory study, plasma concentration of ficolin-3 and of ficolin-3-mediated functional LCP activity was measured, along with that of other LCP initiators (mannose-binding lectin, ficolin-2, and ficolin-1), C3 activation products, and soluble C5b-9 terminal complex, in a prospective cohort of 39 patients with SAH and 20 healthy controls. The following parameters were recorded: SAH severity, assessed using the World Federation of Neurosurgical Societies grading scale; vasospasm, defined as neuro-worsening with angiographic confirmation of vessel narrowing; cerebral ischemia, defined as hypodense lesion on CT scan performed before discharge; and 6-month outcome, assessed using the Glasgow Outcome Scale. RESULTS: In patients, no changes were detected for ficolin-3 compared with controls. Notably, however, ficolin-3-mediated functional LCP activity was reduced. Low levels of plasma ficolin-3 and ficolin-3-mediated functional LCP activity were related to SAH severity, vasospasm, and cerebral ischemia. Moreover, ficolin-3 functional LCP activity was decreased in patients with unfavorable outcome. CONCLUSION: Our data provide evidence that LCP is activated after SAH and that the actual plasma concentrations of ficolin-3 reflect the severity of brain injury as evaluated by clinical and structural parameters. These results support the idea that ficolin-3-mediated functional LCP activity may be targeted to control injury progression in SAH.
OBJECTIVES: To assess the involvement of ficolin-3, the main initiator of the lectin complement pathway (LCP), in subarachnoid hemorrhage (SAH) pathology and outcome. METHODS: In this preliminary exploratory study, plasma concentration of ficolin-3 and of ficolin-3-mediated functional LCP activity was measured, along with that of other LCP initiators (mannose-binding lectin, ficolin-2, and ficolin-1), C3 activation products, and soluble C5b-9 terminal complex, in a prospective cohort of 39 patients with SAH and 20 healthy controls. The following parameters were recorded: SAH severity, assessed using the World Federation of Neurosurgical Societies grading scale; vasospasm, defined as neuro-worsening with angiographic confirmation of vessel narrowing; cerebral ischemia, defined as hypodense lesion on CT scan performed before discharge; and 6-month outcome, assessed using the Glasgow Outcome Scale. RESULTS: In patients, no changes were detected for ficolin-3 compared with controls. Notably, however, ficolin-3-mediated functional LCP activity was reduced. Low levels of plasma ficolin-3 and ficolin-3-mediated functional LCP activity were related to SAH severity, vasospasm, and cerebral ischemia. Moreover, ficolin-3 functional LCP activity was decreased in patients with unfavorable outcome. CONCLUSION: Our data provide evidence that LCP is activated after SAH and that the actual plasma concentrations of ficolin-3 reflect the severity of brain injury as evaluated by clinical and structural parameters. These results support the idea that ficolin-3-mediated functional LCP activity may be targeted to control injury progression in SAH.
Authors: Franca Orsini; Daiana De Blasio; Rosalia Zangari; Elisa R Zanier; Maria-Grazia De Simoni Journal: Front Cell Neurosci Date: 2014-11-07 Impact factor: 5.505
Authors: Stefano Fumagalli; Carlo Perego; Rosalia Zangari; Daiana De Blasio; Marco Oggioni; Francesca De Nigris; Francesco Snider; Peter Garred; Angela M R Ferrante; Maria-Grazia De Simoni Journal: Front Immunol Date: 2017-03-16 Impact factor: 7.561
Authors: Katherine Holste; Fan Xia; Hugh J L Garton; Shu Wan; Ya Hua; Richard F Keep; Guohua Xi Journal: Exp Neurol Date: 2021-02-20 Impact factor: 5.620
Authors: R Zangari; E R Zanier; G Torgano; A Bersano; S Beretta; E Beghi; B Casolla; N Checcarelli; S Lanfranconi; A Maino; C Mandelli; G Micieli; F Orzi; E Picetti; M Silvestrini; N Stocchetti; B Zecca; P Garred; M G De Simoni Journal: J Neuroinflammation Date: 2016-01-20 Impact factor: 8.322
Authors: Franca Orsini; Elvina Chrysanthou; Thomas Dudler; W Jason Cummings; Minoru Takahashi; Teizo Fujita; Gregory Demopulos; Maria-Grazia De Simoni; Wilhelm Schwaeble Journal: J Neuroinflammation Date: 2016-08-30 Impact factor: 8.322